Discounted Cash Flow
Catalyst Pharmaceuticals, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $0 | $-18.1m | $-18.1m | — | $-0.22 |
| 2017 | $0 | $-18.4m (-1.9%) | $-13.7m (23.9%) | — | $-0.21 (4.5%) |
| 2018 | $500.0k | $-34.0m (-84.7%) | $-25.8m (-87.7%) | -6800.7% | $-0.33 (-57.1%) |
| 2019 | $102.3m (20361.3%) | $31.9m (193.7%) | $34.6m (234.1%) | 31.2% (100.5%) | $0.31 (193.9%) |
| 2020 | $118.7m (16.1%) | $75.0m (135.2%) | $45.0m (30.2%) | 63.1% (102.7%) | $0.72 (132.3%) |
| 2021 | $140.8m (18.6%) | $39.5m (-47.3%) | $59.4m (31.8%) | 28.0% (-55.6%) | $0.38 (-47.2%) |
| 2022 | $214.2m (52.1%) | $83.1m (110.4%) | $116.0m (95.5%) | 38.8% (38.3%) | $0.80 (110.5%) |
| 2023 | $398.2m (85.9%) | $71.4m (-14.0%) | $143.4m (23.6%) | 17.9% (-53.8%) | $0.67 (-16.2%) |
| 2024 | $491.7m (23.5%) | $163.9m (129.5%) | $239.3m (66.9%) | 33.3% (85.9%) | $1.38 (106.0%) |
| 2025 | $589.0m (19.8%) | $214.3m (30.8%) | $208.6m (-12.8%) | 36.4% (9.2%) | $1.75 (26.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.